Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc.BBOT · Entity 5215 | Principal Accounting Officer | October 01, 2026 | October 05, 2026 |
| Tricida, Inc.TCDA · Entity 122050 | SVP, Finance & CAO | September 10, 2020 | September 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Oncology Therapeutics, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,015 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Tax withholding · Disposed 126 · Balance 14,015 F1: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Tricida, Inc.
Report date September 10, 2020 · Filed September 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,000 |
Reported balance
After 2020-09-10 transaction · row 1
1 source rowRow 1 · 2020-09-10 · Grant · Acquired 3,000 · Balance 3,000 F1: Represents restricted stock units ("RSUs") that vest on December 31, 2021, subject to the Reporting Person's continuous service through such vesting date. Each RSU represents a contingent right to receive one share of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that vest on December 31, 2021, subject to the Reporting Person's continuous service through such vesting date. Each RSU represents a contingent right to receive one share of Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:14 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | Tax withholdingCommon Stock | 126 | $3.94 | $496.44 |
DisclosureSEC source: 0001193125-26-414135 · ownership.xml · nonDerivative · entry 1 Cobo Marc · CIK 0001816654 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,015 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 20:24 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | GrantStock Option (Right to Buy) · Derivative | 43,700 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001193125-26-390624 · ownership.xml · derivative · entry 3 Cobo Marc · CIK 0001816654 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,700 Underlying: Common Stock · 43,700 shares Expires 2036-09-09 F3 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 20:24 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | Tax withholdingCommon Stock | 203 | $5.52 | $1,120.56 |
DisclosureSEC source: 0001193125-26-390624 · ownership.xml · nonDerivative · entry 2 Cobo Marc · CIK 0001816654 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,141 F2 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 20:24 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | GrantCommon Stock | 9,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-390624 · ownership.xml · nonDerivative · entry 1 Cobo Marc · CIK 0001816654 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,344 F1 · shares: Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:00 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | Tax withholdingCommon Stock | 125 | $7.80 | $975.00 |
DisclosureSEC source: 0001193125-26-296504 · ownership.xml · nonDerivative · entry 1 Cobo Marc · CIK 0001816654 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,306 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 10, 2020 Filed Sep 15, 2020 00:42 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001595585-20-000125 · wf-form4_160013051063469.xml · nonDerivative · entry 1 Cobo Marc · CIK 0001816654 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Represents restricted stock units ("RSUs") that vest on December 31, 2021, subject to the Reporting Person's continuous service through such vesting date. Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 00:14 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $25.55 | $0.00 |
DisclosureSEC source: 0001595585-20-000102 · wf-form4_159364887143225.xml · derivative · entry 1 Cobo Marc · CIK 0001816654 · SVP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-06-28 F1 · derivative.exercise_date: This option will vest 25% on June 29, 2021, and the remaining 75% will vest in 36 substantially equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. The option contained an early-exercise provision and is exercisable as to unvested shares, subject to the issuer's right of repurchase. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.